There is an important unmet need for clinically validated non-invasive biomarkers for SSc diagnosis, assessment of disease activity, extent of internal organ involvement, therapeutic response and prognosis. There is also an unmet need for biomarkers to accurately differentiate primary RP from recent onset RP evolving into SSc. The lack of sensitive and specific biomarkers for SSc and SSc-associated RP is a limitation for the optimal clinical management of these patients. The development of highly sensitive and specific proteomic analysis employing aptamers and the expansion in the number of proteins that can be specifically identified by aptamer proteomics have opened new horizons for biomarker discovery. Here, we review the background and rationale for aptamer proteomic analysis for the identification of novel noninvasive biomarkers for SSc and recent onset RP evolving into SSc. Large scale application of aptamer proteomic platforms for this purpose will be of substantial value for the precision and personalized medical care of SSc patients. These studies will be placed in context by comparison with proteomic biomarker studies performed for other rheumatological inflammatory and autoimmune diseases.
Introduction
SSc is a serious, disabling and often fatal systemic autoimmune disease of unknown etiology characterized by a severe and often progressive cutaneous and visceral fibrotic process accompanied by prominent fibroproliferative vasculopathy of small and large vessels and by almost universally present alterations in innate, humoral and cellular immunity [14] . Despite extensive understanding of the numerous and complex mechanisms and pathways participating in SSc pathogenesis [510] , there is currently no approved disease-modifying therapy for the disease [1114] , and it frequently progresses causing severe disabilities, multiple organ failure and a fatal outcome [15] . Besides the subjective evaluation of the extent and severity of cutaneous induration performed employing a semiquantitative clinical assessment known as the modified Rodnan Skin Score or mRSS [16, 17] , validated non-invasive biomarkers that allow early diagnosis and monitoring of SSc disease activity or that carry a predictive prognostic value are not available [1824] . Although there are already very useful biomarkers and integrated risk scores available for some of the most serious SSc complications such as SSc-associated pulmonary arterial hypertension [2529] some of these risk score assessments involve invasive procedures such as, for example, right side cardiac catheterization [27, 28] . Thus, the limited number of validated, sensitive and specific non-invasive biomarkers for early assessment of extent and severity of SSc organ involvement represents a major unmet need in the clinical management of SSc patients, particularly during the early stages of the disease when therapeutic interventions may be most beneficial and effective in inducing a favourable clinical response.
One of the most common and earliest manifestations of SSc is RP [30, 31] ; however, it is also relatively common in the general population. Whereas primary RP is a benign condition without any internal organ damage or increased mortality risk, SSc-associated RP displays a more serious prognosis including a substantially higher mortality rate [30, 31] . Although immunological tests and serum autoantibody assays have been employed for differentiating primary RP from SSc-associated RP [32, 33] , currently there remains a need for biomarkers capable of accurately establishing this distinction, particularly during the early stages of disease before more serious SSc clinical manifestations or internal organ involvement become apparent.
There has been remarkable recent interest in the proteomic study of serum and other biological fluids as a novel and highly informative platform for the identification of biomarkers for numerous human disorders. The vast majority of these studies have employed mass spectrometry and related procedures for protein identification [3437] . However, these approaches have limitations owing to the complex and time consuming procedures required for peptide preparation and separation followed by complicated mass spectrometry assays. Furthermore, the low concentrations of relevant proteins usually contained in serum, plasma and other biological fluids have also seriously restricted their performance. This serious barrier has been recently surmounted with the introduction of aptamer technologies that allow identification and quantification of a large number of proteins with extremely high sensitivity and specificity. As described in greater detail in subsequent sections, the remarkable increase in the sensitivity of aptamer proteomics in comparison with other more established and generally accepted proteomic platforms has been demonstrated [3841] . A comparison of the dynamic range and sensitivity of aptamer proteomics with other commonly used proteomic platforms for biomarker discovery is shown in Table 1 (adapted from [41] ).
Here, we will review the background and rationale for the application of aptamer proteomic analyses for the identification of novel non-invasive biomarkers for SSc and for the recognition of patients with recent onset RP at risk of evolving into SSc. We will also review briefly the contributions of aptamer technology to the identification of novel non-invasive biomarkers for other inflammatory and autoimmune rheumatological diseases.
Diagnostic and prognostic SSc biomarkers: an unmet need
Despite strong interest in outcome measures for SSc [4244] , non-invasive validated biomarkers that allow early SSc diagnosis and assessment of disease activity or that allow identification of early organ involvement are not available [1824] . Numerous studies have examined histological, biochemical or gene expression alterations of SSc-affected tissues in the search for biomarkers reflective of SSc clinical evolution and efficacy of therapeutic interventions. These studies include a quantitative assessment of hyalinized collagen and of the number of activated myofibroblasts [45] , and measurements of the content of fibrosis-related macromolecules in affected SSc tissues [4648] ; however, these approaches are invasive and have not gained general acceptance. The introduction of global gene expression analysis of SSc-affected tissues employing transcriptome microarrays has provided a wealth of information regarding SSc pathogenesis, molecular and clinical heterogeneity, clinical severity and response to therapeutic interventions [4956] . The unbiased assessment of global gene expression in affected SSc skin biopsies demonstrated that it was possible to consistently identify several molecular patterns that correlated with SSc clinical manifestations, clinical course and disease severity. Furthermore, assessment of global gene expression allowed accurate following of the clinical response to therapeutic interventions as shown by the identification of a specific molecular signature that correlated with clinical improvement during treatment of SSc patients with MMF [55] . Gene expression studies also have the potential to provide accurate molecular stratification of SSc patients that may allow personalized or individualized therapeutic interventions [56] . Furthermore, transcriptomic analysis and other gene expression studies are easy to perform on a large scale and provide the additional Sensitivity mg/ml ng/ml pg/ml pg/ml
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advantages of effective annotation and bioinformatics infrastructure. Despite these highly valuable advantages, it is important to emphasize that gene expression levels do not always correlate with the levels of the corresponding proteins and do not take into consideration that the functional effects of the encoded proteins may depend on or be influenced by crucial post-translational modifications and molecular events that are not identified by global gene expression studies as discussed recently [57] .
Next generation quantitative proteomics employing aptamers
A major challenge to the application of proteomic platforms for disease biomarker identification is that individual proteins that may represent novel biomarkers may have extremely low concentrations and might have escaped identification as potential biomarkers owing to their low abundance in biological fluids, as well as to masking effects caused by proteins present at much higher concentrations. Therefore, the analytical sensitivity of the assays employed to quantify and identify the low concentration of these proteins represents a major barrier for antibodybased or mass spectroscopy proteomic studies for biomarker identification. With the recent development of novel proteomic technologies, however, identification of proteins present in very low concentrations in biological fluids not only has become feasible, but is continuing to expand.
One of the most significant recent advances in quantitative global proteomic assessments was the introduction of aptamer technologies [3841, 5868] . Aptamers are short single-stranded oligonucleotides that can fold into a diverse array of intricate molecular structures possessing the ability to bind with high affinity and extremely high specificity to proteins, peptides and small molecules as depicted in Fig. 1A . The pioneering studies leading to the development of aptamers were first described in 1990 [58, 59] . In one of these studies subpopulations of RNA molecules that bind specifically to a variety of organic dyes were isolated from a large population of random sequence RNA molecules. This study found that about 1 in 10 10 random sequence RNA molecules folds in such a way as to create a specific binding site for small ligands [58] . The application of multiple rounds of signal selection exponentially enriches the population for the highest affinity and specificity species that could subsequently be clonally isolated and characterized [58, 59] . Two key innovations allowed the efficient selection of a novel class of aptamer, the Slow Off-rate Modified Aptamer (SOMAmer) with high-affinity for essentially any protein target and the subsequent development of multiplexed assays for highperformance proteomic analysis known as SOMAscan. The first innovation was the addition of functional groups that mimic amino acid side-chains resulting in an expansion of their chemical diversity [58, 59, 6971] . The second innovation was the development of systematic evolution of ligands by exponential enrichment (SELEX), a process for the selection of aptamers with very slow dissociation rates to allow for the minimization of non-specific aptamerprotein binding. SELEX is a combinatorial procedure that allows the identification of oligonucleotide aptamers through iterative selection/amplification rounds [58, 59, 7275] . The preparation and selection of high affinity specific aptamers are illustrated diagrammatically in Fig. 1B .
Aptamers exhibit highly complex molecular recognition properties and are capable of binding specifically and with high affinity to targets ranging from small molecules to complex multimeric structures [3841] . The aptamerbased proteomic analysis utilizing the SOMAscan assay is a highly multiplexed, sensitive, quantitative and reproducible proteomic platform that allows the discovery of previously undetected biomarkers. As shown in Table 1 , this aptamer approach offers an exceptional dynamic range compared with other proteomic platforms, permitting quantification of protein levels that span over eight orders of magnitude in abundance (from femtomolar to micromolar), with excellent reproducibility and with a low coefficient of variability [3841, 7679] . The current SOMAscan assay measures levels of 1310 analytes in only 65 ml of sample over a wide dynamic range (>8 orders of magnitude of concentration). The analytes assayed include a diverse collection of proteins from all major gene families such as receptors, kinases, growth factors, cytokines, chemokines and hormones, as well as numerous cell-specific intracellular proteins. Furthermore, aptamers display higher affinity and exquisite specificity of interaction with their specific target compared with antibody-based procedures [3841] and it has been suggested that aptamers may replace antibodies for various antibody-mediated assays [80] .
Aptamer proteomics for identification of disease biomarkers
Recently, aptamer proteomic analyses have been applied to the search for disease-specific biomarkers present in a variety of biological fluids including serum, plasma, urine and cerebrospinal fluid, as well as, in various malignant cells, tissues and tumours [7679] . Given the extreme sensitivity and specificity of aptamer proteomics, there have been numerous studies reporting the applicability of whole serum and plasma aptamer measurements as non-invasive biomarkers for a large number of inflammatory, infectious, genetically determined, degenerative and malignant diseases. In the following sections the application of aptamer proteomic analyses for the identification of novel biomarkers for various idiopathic inflammatory diseases, rheumatological inflammatory and autoimmune diseases, and for SSc will be reviewed.
Aptamer proteomic identification of biomarkers for idiopathic non-rheumatological inflammatory diseases
Several studies have employed aptamer proteomic analysis to identify biomarkers of idiopathic inflammatory diseases. One such study performed aptamer analysis of plasma protein levels in patients with idiopathic pulmonary fibrosis (IPF) over the course of up to 80 weeks of treatment and identified a six aptamer panel composed of markers associated with regulation of immune function, proteolysis and angiogenesis that predicted an improvement in progression-free survival [81] . A subsequent and more extensive study examined the differentially expressed proteins in the blood of a large number of IPF patients compared with normal controls [82] . From a total of 1129 proteins analysed, 203 were found to be differentially elevated or reduced in the IPF patients compared with the values obtained for the same proteins in the control individuals. Further analysis of the results allowed the identification of a panel of eight proteins representing a signature that accurately differentiated IPF patients from healthy controls, thus representing a potentially valuable diagnostic biomarker signature. Furthermore, these studies demonstrated that plasma from IPF patients was significantly enriched for proteins involved in important regulatory pathways including host defence response, wound healing and protein phosphorylation [82] . A similar study was recently conducted to identify serum biomarkers that may allow following of the response of children with IBD to disease modifying therapeutic interventions (glucocorticoids or infliximab) using aptamer-based proteomic analysis [83] . The results of this extensive study identified 213 proteins that changed significantly following prednisone treatment and 94 proteins that changed significantly following infliximab therapy. Notably, 18 proteins displayed a consistent and significant response to both therapeutic interventions. Five of these proteins were significantly reduced by either therapy. Of remarkable interest was the observation that several of the proteins displaying changes following the therapeutic interventions were related to the nuclear factor NF-kB pathway [83] .
Identification of disease biomarkers for inflammatory and autoimmune rheumatological diseases employing aptamer proteomic analyses
Two recent studies searched for proteomic biomarkers for rheumatological inflammatory and autoimmune diseases employing aptamer technologies. One study compared the proteomic profiles of serum samples from 16 patients with PsA and 16 patients with RA employing liquid chromatographytandem mass spectrometry, Luminex and SOMAScan platforms to identify differentially expressed proteins in the serum of both groups of patients [84] . The results obtained successfully identified with a high degree of sensitivity and reproducibility differentially expressed proteins present in the serum of these two cohorts of patients. Furthermore, this study demonstrated that the aptamer SOMAScan platform displayed greater sensitivity and allowed quantification of a much larger number of differentially expressed proteins than mass spectroscopy and Luminex assays [84] . The mass spectroscopy analysis identified 42 differentially expressed proteins, the Luminex assay identified three, and the SOMAScan aptamer platform identified 127. The second study performed a quantitative proteomic analysis of serum samples from 28 patients with untreated RA and 30 patients with SS in comparison with 30 healthy control subjects employing the SOMAScan aptamer proteomic multiplexed assay that evaluated the levels of 1128 proteins [85] . This study identified 33 proteins that were differentially elevated in the serum samples of the RA patients. The results were validated employing electrochemiluminescence and ELISA assays and were in agreement with previous results obtained employing conventional methods. The differentially expressed proteins comprised proteins known to be involved in RA pathogenesis including various cytokines, components of inflammatory pathways and MMPs. A novel observation in these studies was that the proinflammatory cytokine IL-16 was among the cytokines markedly elevated in the serum of RA patients and that these levels were strongly reduced following treatment with MTX [85] .
Aptamer proteomics for identification of SSc biomarkers
Although several studies have described proteomic analyses of isolated cells, serum and affected tissues from SSc patients [8688] , none of these utilized aptamer proteomic analysis. A recent study searched for biomarkers present in the serum from SSc patients employing aptamer proteomics for this purpose [89] . This study analysed serum proteins using SOMAScan aptamer technology in two cohorts of patients with early diffuse SSc of < 2 years from the first non-Raynaud's symptom in comparison with healthy control subjects. The results demonstrated that using stringent statistical significance criteria 16% of serum proteins in the aptamer panel were differentially expressed between SSc patients and normal controls and that these proteins correlated with the mRSS. Comparison of the results obtained with the two SSc patient cohorts showed that 61% of the proteins identified in the first cohort were also identified in the second cohort. Further analysis of the results confirmed the crucial role of TNF-a, TGF-b and IL-13 in the expression of molecular pathway differences between SSc patients and healthy controls. Furthermore, the pathway analysis of the differentially expressed proteins in this study identified numerous proteins not previously associated with SSc that may be involved in its pathogenesis and, therefore, may represent novel potential targets for therapeutic intervention. Remarkably, two of the novel identified proteins (ST2 and spondin-1) together constituted a robust longitudinal SSc biomarker that may be of great value and utility for monitoring changes in disease state over time [89] .
Aptamer proteomic analysis of exosomes for biomarker identification
Exosomes are lipid bilayer membrane bound microvesicles released from all human cells into their surrounding intercellular space and into the circulation [9095] . Exosomes comprise a well-defined subtype of microvesicles identified based on their size, the mechanisms of their production and secretion from cells, and their peculiar content or cargo. Exosomes contain a large number of macromolecules including nucleic acids (DNA fragments, mRNAs, non-coding RNAs and miRNAs), proteins and lipids [90, 92, 9698] . It has been shown that the macromolecular content of exosomes depends on their cell of origin and, more importantly, reflects the functional or pathological status of the cells. Therefore, there has been great interest in the study of exosomal content, particularly of miRNAs and proteins, cytokines and inflammatory mediators as potential diagnostic biomarkers for a variety of diseases.
There are large numbers of proteins in exosomes that are either localized in the exosome membrane or are contained inside the exosome representing the exosome core proteins. The most important proteins contained in exosomes are diagrammatically illustrated in Fig. 2 . There has been intense recent interest in characterizing the protein composition of exosomes for the generation of non-invasive biomarkers for disease diagnosis, prognosis and response to therapeutic interventions [9093, 97, 98] . The most useful types of proteomic information are typically derived from quantitative data on protein expression levels that allow identification of exosomal protein differences between exosomes from normal individuals and exosomes isolated from patients with various pathological conditions as diagnostic biomarkers or as biomarkers for the assessment of disease extent and severity or response to therapy. The vast majority of these studies were performed employing standard proteomic platforms such as mass spectroscopy or matrix-assisted laser desorption/ionization time of flight mass spectrometry. Owing to the extremely high sensitivity and specificity inherent in the application of aptamer proteomic technology, there has been great recent interest in applying such technology for the characterization and quantitative analysis of the protein cargo of exosomes. To our knowledge, there are only a few studies that employed aptamer proteomics to analyse the protein cargo of purified exosomes. In one such study, the protein content of cultured prostate cancer cells was analysed and compared with the protein content of exosomes secreted by these cells into the culture medium employing aptamer proteomic assays [99] . As a result of the study, over 300 proteins not previously associated with cancer exosomes were identified and it was found that almost 100 proteins were enriched in exosomes purified from the culture medium compared with the proteins contained within the cultured cells. Additionally, several proteins with no previously known exosomal association were identified demonstrating the remarkable sensitivity and analytical power of the application of aptamer proteomic procedures to examine the protein cargo of isolated exosomes [99] . Thus, the application of aptamer proteomic studies to examine and characterize the proteomic content of purified exosomes should result in even further improvement in the ability to identify disease-specific biomarkers.
Conclusions
Aptamer protein assays have demonstrated a tremendous potential for the discovery, identification and validation of biomarkers for a variety of human disorders. Given the high sensitivity and specificity of aptamers and their multiple applications as tools for biomarker identification, it has been suggested that aptamer proteomic analysis may eventually replace the utilization of antibodies for the identification and quantification of protein biomarkers [40, 80] . Thus, it is expected that the use of aptamers for the discovery of disease-specific biomarkers should continue to expand enhancing their value as diagnostic tools in the rapidly developing field of individualized medicine.
Application of aptamer proteomics to the analysis of biological fluids obtained from SSc patients and from patients with RP should provide extremely sensitive and specific non-invasive biomarkers for the diagnosis of SSc, for the identification of patients with RP evolving into SSc, and for the assessment of the extent, severity and progression of SSc organ involvement. Aptamer proteomics should also allow the identification of highly sensitive biomarkers for the evaluation of clinical responses to SSc disease modifying therapeutic interventions and for the prognosis of the clinical outcome of patients with SSc. Furthermore, the high sensitivity and specificity of aptamer platforms for the large scale and multiplexed identification of biomarkers will be of substantial value for the expansion of precision and personalized medical care for patients with SSc. 
